Medical Developments International Ltd profit soars: Should you buy?

Medical Developments International Ltd (ASX:MVP) reported stellar earning results today. With huge international expansion plans, is the stock a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Medical Developments International Ltd (ASX: MVP), which develops and supplies specialised healthcare products to Australian and international markets, reported a 72% increase in net profit of $731,000 on $5.5 million of revenue for the six months to December 31, 2014.

Cash flow from operations increased 330% on the back of an 18% increase in revenues over the prior corresponding period (pcp). This was used to pay off $2.1 million of debt, reducing net debt by 57% to $1.6 million.

No interim dividend was declared by the board.

Chairman David Williams' personal holding in the company is now over 50%, ensuring the interests of management and investors are aligned.

Products

Medical Developments' main products include asthma respiratory devices and the short-term pain management drug Penthrox. Many people will recognise Penthrox in its final form as the "green whistle", a standard item in the equipment bag of paramedics. Penthrox is non-addictive and does not require secure storage, giving a distinct advantage over similar opioid drugs such as morphine.

Whilst the company has numerous other products, Penthrox and asthma products are the main drivers for future growth and generated 65% of total revenue, up from 57% in the pcp.

A joint venture project with CSIRO that should revolutionise the manufacturing process and dramatically reduce the cost base is expected to be completed during the 2015 financial year.

Global ambition

Australia and New Zealand are currently the main markets for Medical Developments but this is quickly changing. Management is now focusing on expanding its product suite internationally. It appears to be working. International revenue now counts for 19% of total revenue, up from 12% in the pcp.

Last month approval was given for the company to sell Penthrox into Britain, France, Belgium and Ireland. The Australian Business Review reported that "in financial 2014, Penthrox achieved sales of around $6 million in Australia. The British market alone represents three times that amount."

Applications to sell Penthrox have been submitted to Israel, Singapore, Saudi Arabia and Russia, whilst the company is in the final stages of the application process in Hungary, Mexico, Malaysia and Hong Kong.

Asthma devices are already being distributed and sold throughout Australia, New Zealand, Europe and North America. Management expect the second half of the year to show ongoing improvement in sales.

Outlook

Over the past three months the share price has soared from $1.15 to the current price around $2.00. Penthrox will need to become an integral part of pain management in international markets to justify Medical Developments' sky-high price earnings ratio over 80. Any setbacks in approvals or poor traction in sales could see the share price hammered.

I recommend investors monitor the success of the international expansion over the next year before buying in at the current price.

Motley Fool contributor Mitch Sonogan owns shares in Medical Developments International Ltd.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »